Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2006 1
2012 2
2019 1
2020 1024
2021 1422
2022 1173
2023 707
2024 420
2025 338
2026 153

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,676 results

Results by year

Filters applied: . Clear all
Page 1
Remdesivir.
Bakheit AH, Darwish H, Darwish IA, Al-Ghusn AI. Bakheit AH, et al. Profiles Drug Subst Excip Relat Methodol. 2023;48:71-108. doi: 10.1016/bs.podrm.2022.11.003. Epub 2023 Feb 9. Profiles Drug Subst Excip Relat Methodol. 2023. PMID: 37061276 Free PMC article. Review.
Remdesivir, marketed under the brand name Veklury, is an antiviral drug with a broad spectrum of activity. There were various countries where the use of Remdesivir for the treatment of COVID-19 was authorized during the pandemic. Remdesivir was first designed …
Remdesivir, marketed under the brand name Veklury, is an antiviral drug with a broad spectrum of activity. There were various countri …
Retrospective study and outcome of 307 cats with feline infectious peritonitis treated with legally sourced veterinary compounded preparations of remdesivir and GS-441524 (2020-2022).
Taylor SS, Coggins S, Barker EN, Gunn-Moore D, Jeevaratnam K, Norris JM, Hughes D, Stacey E, MacFarlane L, O'Brien C, Korman R, McLauchlan G, Salord Torres X, Taylor A, Bongers J, Espada Castro L, Foreman M, McMurrough J, Thomas B, Royaux E, Calvo Saiz I, Bertoldi G, Harlos C, Work M, Prior C, Sorrell S, Malik R, Tasker S. Taylor SS, et al. J Feline Med Surg. 2023 Sep;25(9):1098612X231194460. doi: 10.1177/1098612X231194460. J Feline Med Surg. 2023. PMID: 37732386 Free PMC article.
Three treatment protocols were used; remdesivir alone (33.9%), remdesivir followed by GS-441524 (55.7%) and GS-441524 alone (10.4%). ...CONCLUSIONS AND RELEVANCE: Legally sourced remdesivir and GS-441524 products, either alone or used sequentially, were very …
Three treatment protocols were used; remdesivir alone (33.9%), remdesivir followed by GS-441524 (55.7%) and GS-441524 alone (1 …
Remdesivir-Induced Bradycardia.
Kanagala SG, Dholiya H, Jhajj P, Patel MA, Gupta V, Gupta S, Wu SI, Jain R. Kanagala SG, et al. South Med J. 2023 Mar;116(3):317-320. doi: 10.14423/SMJ.0000000000001519. South Med J. 2023. PMID: 36863055 Free PMC article. Review.
Remdesivir, a viral RNA-dependent RNA polymerase inhibitor, found extensive use in coronavirus disease 2019-infected patients because it curbs the viral load expansion. Among patients hospitalized as a result of lower respiratory tract infection, remdesivir proved t …
Remdesivir, a viral RNA-dependent RNA polymerase inhibitor, found extensive use in coronavirus disease 2019-infected patients because …
A Systematic Review and Meta-analysis of the Effectiveness of Remdesivir to Treat SARS-CoV-2 in Hospitalized Patients: Have the Guidelines Evolved With the Evidence?
Bartoletti M, Mozaffari E, Amin AN, Doi Y, Loubet P, Rivera CG, Roshon M, Rawal A, Kaiser E, Vutcovici Nicolae M, Fu S, Oppelt TF, Chiang M, Sax PE, Kalil AC. Bartoletti M, et al. Clin Infect Dis. 2025 Aug 1;81(1):20-29. doi: 10.1093/cid/ciaf111. Clin Infect Dis. 2025. PMID: 40067859 Free PMC article.
We conducted a systematic literature review with meta-analysis to summarize the effectiveness of remdesivir among hospitalized adults. METHODS: We systematically searched MEDLINE, Embase and Cochrane Library databases for interventional and observational studies examining …
We conducted a systematic literature review with meta-analysis to summarize the effectiveness of remdesivir among hospitalized adults …
Remdesivir-Associated Pancreatitis.
Khadka S, Williams K, Solanki S. Khadka S, et al. Am J Ther. 2022 Jul 1;29(4):e444-e446. doi: 10.1097/MJT.0000000000001266. Am J Ther. 2022. PMID: 33590992
Withdrawal of remdesivir paired with medical management of acute pancreatitis led to the resolution of pancreatitis within three days. To our knowledge, this is the first case report depicting remdesivir as a possible cause of acute pancreatitis....
Withdrawal of remdesivir paired with medical management of acute pancreatitis led to the resolution of pancreatitis within three days …
Efficacy and Safety of Remdesivir in People With Impaired Kidney Function Hospitalized for COVID-19 Pneumonia: A Randomized Clinical Trial.
Sise ME, Santos JR, Goldman JD, Tuttle KR, Teixeira JP, Seibert AF, Koullias Y, Llewellyn J, Regan S, Zhao Y, Huang H, Hyland RH, Osinusi A, Winter H, Humeniuk R, Hulter HN, Gottlieb RL, Fusco DN, Birne R, Stancampiano FF, Libertin CR, Small CB, Plate M, McPhail MJ; REDPINE Investigators. Sise ME, et al. Clin Infect Dis. 2024 Nov 22;79(5):1172-1181. doi: 10.1093/cid/ciae333. Clin Infect Dis. 2024. PMID: 38913574 Free PMC article. Clinical Trial.
RESULTS: Although enrollment concluded early, 243 participants were enrolled and treated (remdesivir, n = 163; placebo, n = 80). At baseline, 90 participants (37.0%) had acute kidney injury (remdesivir, n = 60; placebo, n = 30), 64 (26.3%) had chronic kidney disease …
RESULTS: Although enrollment concluded early, 243 participants were enrolled and treated (remdesivir, n = 163; placebo, n = 80). At b …
Remdesivir and Its Combination With Repurposed Drugs as COVID-19 Therapeutics.
Chatterjee B, Thakur SS. Chatterjee B, et al. Front Immunol. 2022 May 12;13:830990. doi: 10.3389/fimmu.2022.830990. eCollection 2022. Front Immunol. 2022. PMID: 35634324 Free PMC article. Review.
Better results were obtained with the remdesivir-baricitinib combination treatment for COVID-19 compared to the treatment with remdesivir alone. Notably, recovery from COVID-19 was found to be 8 days less via the remdesivir-baricitinib combination treatment a …
Better results were obtained with the remdesivir-baricitinib combination treatment for COVID-19 compared to the treatment with rem …
Remdesivir-related cost-effectiveness and cost and resource use evidence in COVID-19: a systematic review.
Murton M, Drane E, Jarrett J, Cornely OA, Soriano A. Murton M, et al. Infection. 2023 Apr;51(2):285-303. doi: 10.1007/s15010-022-01930-8. Epub 2022 Oct 12. Infection. 2023. PMID: 36224452 Free PMC article.
RESULTS: Eight studies reported resource use and five reported costs related to remdesivir. Over time, the prescription rate of remdesivir increased and time from disease onset to remdesivir initiation decreased. Remdesivir was associated with a 6% to …
RESULTS: Eight studies reported resource use and five reported costs related to remdesivir. Over time, the prescription rate of re …
Outcomes of treatment of cats with feline infectious peritonitis using parenterally administered remdesivir, with or without transition to orally administered GS-441524.
Coggins SJ, Norris JM, Malik R, Govendir M, Hall EJ, Kimble B, Thompson MF. Coggins SJ, et al. J Vet Intern Med. 2023 Sep-Oct;37(5):1772-1783. doi: 10.1111/jvim.16803. Epub 2023 Jul 13. J Vet Intern Med. 2023. PMID: 37439383 Free PMC article.
Investigation into the use of parent nucleotide analog remdesivir (GS-5734) is needed. OBJECTIVES: To assess efficacy and tolerability of remdesivir with or without transition to GS-441524 in cats with FIP and document clinical and clinicopathologic progression over …
Investigation into the use of parent nucleotide analog remdesivir (GS-5734) is needed. OBJECTIVES: To assess efficacy and tolerabilit …
Remdesivir: First Approval.
Lamb YN. Lamb YN. Drugs. 2020 Sep;80(13):1355-1363. doi: 10.1007/s40265-020-01378-w. Drugs. 2020. PMID: 32870481 Free PMC article. Review.
The antiviral agent remdesivir (Veklury( ); Gilead Sciences), nucleotide analogue prodrug, has broad-spectrum activity against viruses from several families. ...Phase III evaluation of remdesivir in the treatment of COVID-19 commenced in early 2020 and has thus far …
The antiviral agent remdesivir (Veklury( ); Gilead Sciences), nucleotide analogue prodrug, has broad-spectrum activity against viruse …
4,676 results